Inozyme Stock Based Compensation from 2010 to 2025

INZY Stock

USD 1.19 0.07 6.25%

Inozyme Pharma Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 4.6 M in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2019-03-31

Previous Quarter

2.2 M

Current Value

2.1 M

Quarterly Volatility

805.7 K

Covid

Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.9 M, Interest Income of 4.9 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.

Check out the analysis of Inozyme Pharma Correlation against competitors.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Inozyme Pharma over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Inozyme Pharma's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Inozyme Stock Based Compensation Regression Statistics

	Arithmetic Mean	2,571,270
	Geometric Mean	1,125,849
	Coefficient Of Variation	121.95
	Mean Deviation	2,709,871
	Median	444,000
	Standard Deviation	3,135,632
	Sample Variance	9.8T
	Range	7.8M
	R-Value	0.79
	Mean Square Error	3.9T
	R-Squared	0.63
	Significance	0.0003
	Slope	521,799
	Total Sum of Squares	147.5T

Inozyme Stock Based Compensation History

	2025	4.6 M
	2024	8.1 M
	2023	7 M
	2022	7.7 M
	2021	7.2 M
	2020	2.3 M
	2019	301 K

Other Fundumenentals of Inozyme Pharma

Stock Based Compensation To Revenue

Inozyme Pharma Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.97	0.94	0.15	-0.91	0.59	0.83	0.94	0.93	-0.48	0.87	0.94	1.0	1.0	0.85	0.78	0.83	0.67	0.79	-0.42
Total Stockholder Equity	0.97		1.0	0.01	-0.87	0.76	0.72	0.91	0.94	-0.68	0.85	0.94	0.96	0.95	0.77	0.87	0.81	0.72	0.64	-0.36
Net Tangible Assets	0.94	1.0		-0.06	-0.84	0.81	0.66	0.88	0.92	-0.73	0.84	0.92	0.93	0.92	0.71	0.88	0.78	0.72	0.56	-0.32
Net Debt	0.15	0.01	-0.06		-0.45	-0.4	0.44	0.25	0.26	0.35	0.11	0.2	0.19	0.19	0.52	0.03	0.53	0.46	0.56	-0.44
Retained Earnings	-0.91	-0.87	-0.84	-0.45		-0.5	-0.88	-0.95	-0.96	0.41	-0.81	-0.94	-0.92	-0.91	-0.95	-0.73	-0.92	-0.84	-0.8	0.57
Accounts Payable	0.59	0.76	0.81	-0.4	-0.5		0.29	0.61	0.69	-0.95	0.62	0.66	0.55	0.54	0.36	0.81	0.45	0.61	0.02	-0.21
Net Receivables	0.83	0.72	0.66	0.44	-0.88	0.29		0.93	0.84	-0.16	0.69	0.89	0.84	0.84	0.97	0.51	0.68	0.54	0.91	-0.78
Short Term Investments	0.94	0.91	0.88	0.25	-0.95	0.61	0.93		0.97	-0.51	0.82	0.99	0.93	0.93	0.94	0.77	0.79	0.72	0.79	-0.68
Capital Surpluse	0.93	0.94	0.92	0.26	-0.96	0.69	0.84	0.97		-0.61	0.84	0.98	0.92	0.92	0.91	0.83	0.87	0.84	0.7	-0.6
Total Liab	-0.48	-0.68	-0.73	0.35	0.41	-0.95	-0.16	-0.51	-0.61		-0.42	-0.58	-0.44	-0.43	-0.27	-0.78	-0.42	-0.61	0.06	0.18
Deferred Long Term Liab	0.87	0.85	0.84	0.11	-0.81	0.62	0.69	0.82	0.84	-0.42		0.8	0.86	0.86	0.69	0.79	0.78	0.7	0.59	-0.34
Net Invested Capital	0.94	0.94	0.92	0.2	-0.94	0.66	0.89	0.99	0.98	-0.58	0.8		0.94	0.93	0.91	0.8	0.8	0.74	0.75	-0.64
Total Current Assets	1.0	0.96	0.93	0.19	-0.92	0.55	0.84	0.93	0.92	-0.44	0.86	0.94		1.0	0.86	0.76	0.84	0.67	0.82	-0.43
Net Working Capital	1.0	0.95	0.92	0.19	-0.91	0.54	0.84	0.93	0.92	-0.43	0.86	0.93	1.0		0.86	0.75	0.83	0.65	0.83	-0.43
Common Stock	0.85	0.77	0.71	0.52	-0.95	0.36	0.97	0.94	0.91	-0.27	0.69	0.91	0.86	0.86		0.57	0.8	0.71	0.88	-0.76
Property Plant Equipment	0.78	0.87	0.88	0.03	-0.73	0.81	0.51	0.77	0.83	-0.78	0.79	0.8	0.76	0.75	0.57		0.78	0.79	0.38	-0.3
Current Deferred Revenue	0.83	0.81	0.78	0.53	-0.92	0.45	0.68	0.79	0.87	-0.42	0.78	0.8	0.84	0.83	0.8	0.78		0.92	0.69	-0.37
Short Term Debt	0.67	0.72	0.72	0.46	-0.84	0.61	0.54	0.72	0.84	-0.61	0.7	0.74	0.67	0.65	0.71	0.79	0.92		0.43	-0.42
Long Term Debt	0.79	0.64	0.56	0.56	-0.8	0.02	0.91	0.79	0.7	0.06	0.59	0.75	0.82	0.83	0.88	0.38	0.69	0.43		-0.57
Long Term Debt Total	-0.42	-0.36	-0.32	-0.44	0.57	-0.21	-0.78	-0.68	-0.6	0.18	-0.34	-0.64	-0.43	-0.43	-0.76	-0.3	-0.37	-0.42	-0.57

Click cells to compare fundamentals

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Stock Based Compensation	8.1 M	4.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inozyme Stock Based Compensation from 2010 to 2025

Latest Inozyme Pharma's Stock Based Compensation Growth Pattern

Inozyme Stock Based Compensation Regression Statistics

Inozyme Stock Based Compensation History

Other Fundumenentals of Inozyme Pharma

Inozyme Pharma Stock Based Compensation component correlations

About Inozyme Pharma Financial Statements

Also Currently Popular

Additional Tools for Inozyme Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY